News
The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...
What Happened: The FDA on Thursday approved broader use of Moderna’s mRESVIA vaccine for younger at-risk adults based on late-stage trial results, reported Reuters.
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the ...
Moderna’s RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines.
The U.S. Food and Drug Administration has approved Moderna’s (NASDAQ:MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 who are at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results